China Sky One cleared for AMEX

1 June 2008

China Sky One Medical, a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, says that its common shares have been approved for listing on the American Stock Exchange. The company expects to begin trading on AMEX under the symbol CSY. This approval is contingent upon China Sky One Medical being in compliance with all applicable listing standards on the date it begins trading on the AMEX and may be rescinded if the firm is not. Concurrent with its first trade on AMEX, the company will no longer be quoted on the Over-the-Counter Bulletin Board.

"Our listing on the AMEX is an important milestone for China Sky One Medical," said Yanqin Yu, chief executive, adding: "this provides access to a much broader investment base and should better position us to execute our future initiatives. We look forward to continuing to deliver outstanding returns for our shareholders."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight